Henrik Christian Bidstrup Christian Bidstrup Leffers

Dr. Henrik Christian Bidstrup Christian Bidstrup Leffers


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2011 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
HLHenrik Christian Bidstrup Christian Bidstrup Leffers
Henrik Christian Bidstrup Christian Bidstrup Leffers
MØMikkel Østergaard
Mikkel Østergaard
BGBente Glintborg
Bente Glintborg
NKNiels Steen Krogh
Niels Steen Krogh
HFHeidi Foged
Heidi Foged
MHMerete Lund Hetland
Merete Lund Hetland
Objectives To describe drug survival, disease activity and clinical response in patients with rheumatoid arthritis (RA) treated with abatacept or tocilizumab in routine care, based on prospectively registered observational data from the nationwide Danish DANBIO registry. Methods 150 Patients with RA treated with abatacept and 178 treated with tocilizumab were identified. Drug survival was investigated. Response data were available in 104 and 97 patients, respectively. Changes in 28-joint Disease Activity Score (DAS28) based on C-reactive protein (CRP) and European League Against Rheumatism (EULAR) response after 24 and 48 weeks were investigated. No direct comparison of drugs was made. Results Median (IQR) disease duration was 8.5 (3–14)/9 (3–12) years (abatacept/tocilizumab). 95%/93% of patients had previously received one or more tumour necrosis factor inhibitor (TNFi). After 48 weeks, 54%/64% of patients (abatacept/tocilizumab) maintained treatment. Among patients with available response data, DAS28 was 5.3 (4.7–6.1), 3.4 (2.7–4.9) and 3.3 (2.5–4.3) at baseline, weeks 24 and 48, respectively, in the abatacept group and 5.4 (4.7–6.2), 2.9 (2.3–4.0) and 2.5 (1.9–4.5) in the tocilizumab group. At weeks 24 and 48, the remission rates for abatacept/tocilizumab were 19%/39% and 26%/58%, respectively. EULAR good-or-moderate response rates were 70%/88% and 77%/84%, respectively. The decline in DAS28 variables over time appeared similar between drugs, except for CRP, which seemed to decline more rapidly among tocilizumab-treated patients. Conclusions In patients with RA (≥90% TNFi failures), a good-or-moderate EULAR response was achieved in ≥70% of patients treated with abatacept or tocilizumab for 24 weeks in routine care. Apparent declines in DAS28 variables over time were similar between drugs, except for the more rapid CRP decline among tocilizumab-treated patients, directly caused by interleukin 6 inhibition.

1 April 2019 in Autoimmunity Reviews
Verified
Journal Article
Open access
HLHenrik Christian Bidstrup Christian Bidstrup Leffers
Henrik Christian Bidstrup Christian Bidstrup Leffers
TLTheis Lange
Theis Lange
CCChristopher Collins
Christopher Collins
CUConstance Jensina Ulff-Møller
Constance Jensina Ulff-Møller
SJSvein Ketil Jacobsen
Svein Ketil Jacobsen
Systemic lupus erythematosus (SLE) is a systemic inflammatory autoimmune disease characterized by a broad spectrum of clinical and serological manifestations. This may reflect a complex and multifactorial etiology involving several identified genetic and environmental factors, though not explaining the full risk of SLE. Established SLE risk genotypes are either very rare or with modest effect sizes and twin studies indicate that other factors besides genetics must be operative in SLE etiology. The exposome comprises the cumulative environmental influences on an individual and associated biological responses through the lifespan. It has been demonstrated that exposure to silica, smoking and exogenous hormones candidate as environmental risk factors in SLE, while alcohol consumption seems to be protective. Very few studies have investigated potential gene-environment interactions to determine if some of the unexplained SLE risk is attributable hereto. Even less have focused on interactions between specific risk genotypes and environmental exposures relevant to SLE pathogenesis. Cohort and case-control studies may provide data to suggest such biological interactions and various statistical measures of interaction can indicate the magnitude of such. However, such studies do often have very large sample-size requirements and we suggest that the rarity of SLE to some extent can be compensated by increasing the ratio of controls. This review summarizes the current body of knowledge on gene-environment interactions in SLE. We argue for the prioritization of studies that comprise the increasing details available of the genome and exposome relevant to SLE as they have the potential to disclose new aspects of SLE pathogenesis including phenotype heterogeneity.

22 July 2021 in Lupus Science & Medicine
Verified
Journal Article
Open access
PDF file
AZAmanda Hempel Zinglersen
Amanda Hempel Zinglersen
KIKatrine Kjær Iversen
Katrine Kjær Iversen
HLHenrik Christian Bidstrup Christian Bidstrup Leffers
Henrik Christian Bidstrup Christian Bidstrup Leffers
ELEsben Laugesen
Esben Laugesen
JFJesper Fleischer
Jesper Fleischer
SJSvein Ketil Jacobsen
Svein Ketil Jacobsen
Objectives Cardiovascular autonomic neuropathy (CAN) may affect the clinical course of SLE leading to reduced quality of life. CAN is assessed by heart rate variability (HRV) measures and cardiovascular autonomic reflex tests (CARTs). In patients with SLE, we aimed to determine the characteristics of CAN and if CAN associates with health-related quality of life (HRQoL). Methods Patients with SLE and healthy controls (HCs) were CAN tested with 5 min HRV and three CARTs to determine parameters reflecting parasympathetic and mixed sympathetic–parasympathetic function. Subjects were classified as having no, early or definitive CAN by having none, one or more than one abnormal CART, respectively. HRQoL as determined by the Short Form 12 (SF-12) was assessed in SLE. Results Of 111 patients with SLE, 92 answered the SF-12 and 54 were matched with 54 HCs for characterisation of CAN. Definitive CAN was present in 24.1% (95% CI 15% to 37%) patients with SLE and 1.9% (95% CI 0.3% to 9.8%) HCs (OR 16.8, 95% CI 2.1 to 133.8, p=0.008). The corresponding prevalences of any CAN were 53.7% (95% CI 41% to 66%) and 22.6% (95% CI 13% to 35%). SLE patients with definitive CAN showed signs of mixed sympathetic–parasympathetic dysfunction, whereas patients without CAN primarily presented with impaired parasympathetic activity. Signs of parasympathetic as well as sympathetic–parasympathetic dysfunction were associated with low physical SF-12 component score (all: β>0.211, p<0.05). The mental SF-12 component score was not associated with any CAN indices. Conclusions CAN was a frequent finding in SLE and associated to self-report on impaired physical HRQoL. Even patients without CAN showed signs of impaired parasympathetic function compared with controls.

1 July 2002 in Cell Biology International
Verified
Journal Article
Closed access
PDF file
LALene Aarenstrup
Lene Aarenstrup
AFAnne‐Marie Falch
Anne‐Marie Falch
KJKirsten K. Jakobsen
Kirsten K. Jakobsen
SNSøren Neve
Søren Neve
LHLinda Ø Henriksen
Linda Ø Henriksen
KKKarsten Kristiansen
Karsten Kristiansen

2 April 2021 in Lupus Science & Medicine
Verified
Journal Article
Open access
PDF file
HLHenrik Christian Bidstrup Christian Bidstrup Leffers
Henrik Christian Bidstrup Christian Bidstrup Leffers
ATAnne Troldborg
Anne Troldborg
AVAnne Voss
Anne Voss
SKSalome Kristensen
Salome Kristensen
JLJesper Lindhardsen
Jesper Lindhardsen
SJSvein Ketil Jacobsen
Svein Ketil Jacobsen
Objectives SLE displays large clinical heterogeneity that beyond genetic factors may be determined by environmental exposures. In this Danish nationwide study, we aimed to determine if clinical subsets of SLE were associated with smoking history. Methods At each of six participating centres, incident or prevalent inpatients and outpatients with SLE were consecutively included. Manifestations forming the basis of SLE classification were registered in an electronic chart system. Patients also provided questionnaire-based data on environmental exposures, including smoking history. Hierarchical cluster analysis was conducted to determine and characterise subsets of patients with similar traits of disease manifestations. Levels of smoking exposure by pack-years were correlated to the identified SLE subsets, as well as discrete SLE manifestations. Results The cohort consisted of 485 patients (88% women and 92% Caucasian) with SLE of which 51% were ever smokers. Common disease manifestations comprised non-erosive arthritis (81%), malar rash (57%), lymphopenia (55%), photosensitivity (50%) and persistent proteinuria (41%). We identified three distinct phenotypic clusters characterised by their preponderance of (A) neurological, serosal and mucosal involvement; (B) renal, haematological and immunological disorders; and (C) acute and chronic skin manifestations. Cluster B was the youngest and had the lowest level of smoking exposure. Age-adjusted regression analyses showed that compared with never smokers a smoking history of >20 pack-years was associated with neurological disorder (OR=3.16), discoid rash (OR=2.22), photosensitivity (OR=2.19) and inversely with haematological disorder (OR=0.40), renal disorder (OR=0.40) and non-erosive arthritis (OR=0.45), p<0.05 for all. Conclusions Our findings support that SLE presents in varying clinical phenotypes and suggest that they may have differentiated associations with smoking history.

8 January 2024 in Clinical and Experimental Rheumatology
Verified
Journal Article
Closed access
HLHenrik Christian Bidstrup Christian Bidstrup Leffers
Henrik Christian Bidstrup Christian Bidstrup Leffers
BBBo Baslund
Bo Baslund
JLJesper Lindhardsen
Jesper Lindhardsen
SKSophine Boysen Krintel
Sophine Boysen Krintel
NGNiels Graudal
Niels Graudal
Full Papers; Authors: H.C.B. Leffers, B. Baslund, J. Lindhardsen, S.B. Krintel, N. Graudal